TTRANSLATE - ATTR Study
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized yet frequently underdiagnosed cause of heart failure, particularly among older adults. The American Heart Association’s 2026 Heart Disease and Stroke Statistics Update reports that up to 13% of older adults hospitalized with heart failure with preserved ejection fraction may have ATTR‑CM, underscoring substantial opportunities to improve diagnosis in routine clinical care.
The American Heart Association, a relentless force changing the future of health for everyone, everywhere, has launched a multicenter cluster randomized trial to evaluate whether a structured, provider-focused educational intervention can improve diagnostic testing and confirmed diagnosis of ATTR‑CM among patients hospitalized with heart failure.
The trial, known as TTRANSLATE‑ATTR, is actively enrolling and collecting data across hospitals participating in the Association’s Get With The Guidelines® - Heart Failure quality improvement program. Participating sites are randomized as part of the study design to evaluate the impact of a structured educational intervention compared with usual care.
Why This Study is Innovative
TTRANSLATE‑ATTR is among the first cluster randomized trials to test whether structured, provider‑focused education can measurably improve recognition of transthyretin amyloid cardiomyopathy (ATTR‑CM) within everyday hospital practice. By embedding the intervention directly into the American Heart Association’s Get With The Guidelines® – Heart Failure infrastructure, the study evaluates change not in theory, but at the point of care, across diverse hospitals nationwide. This design allows findings to be immediately relevant, scalable, and reflective of real‑world clinical workflows.
What the Study Intends to Solve
ATTR‑CM is a frequently missed cause of heart failure, particularly among older adults, despite growing evidence of its prevalence and clinical impact. Many patients remain undiagnosed because testing is not consistently considered during hospitalization. This study seeks to address those gaps by equipping clinicians with targeted education designed to prompt appropriate diagnostic evaluation, helping ensure that patients who may have ATTR‑CM are identified earlier and more reliably during routine hospital care.
How Success Will Be Measured
Success will be measured by comparing site‑level rates of ATTR‑CM diagnostic testing and confirmed diagnoses between hospitals receiving the structured educational intervention and those providing usual care. Leveraging data from the Get With The Guidelines – Heart Failure registry, the trial will assess variation across hospitals and evaluate changes before and after the intervention. Evidence of increased testing and diagnosis would demonstrate that targeted education can drive measurable improvements in clinical practice and inform future nationwide dissemination.
AstraZeneca provides financial support for the TRANSLATE-ATTR trial